Pediatric Vaccine Market
Pediatric Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit & Conjugate Vaccines, mRNA Vaccines, Viral Vector Vaccines), By Vaccine Composition (Monovalent, Multivalent), By Technology Platform (Traditional, Next-Generation), By End-User (Hospitals, Pediatric Clinics, Community Health Centers), Forecast Period (2026-2035)
Industry Overview
Pediatric vaccine market size was valued at $31.80 billion in 2025 and is projected to reach $62.50 billion by 2035, growing at a CAGR of 6.30% between 2026 and 2035. The market comprises vaccines designed to prevent infectious diseases in children, forming a critical component of global public health systems. A key driver supporting market growth is the expansion of immunization coverage worldwide. According to the World Health Organization (WHO), immunization prevents approximately 3.5 to 5 million deaths annually, while more than 110 million infants receive vaccines each year globally. Additionally, organizations such as the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) emphasize the importance of vaccines in reducing healthcare costs and disease burden. The adoption of combination vaccines, mRNA platforms, and viral vector technologies is transforming the industry by improving vaccine efficacy and reducing the number of required doses. Pediatric vaccines are widely used across hospitals, pediatric clinics, and community vaccination programs, particularly in developing regions where government initiatives are expanding healthcare access. Increasing investments in vaccine R&D, cold chain infrastructure, and global immunization programs are further accelerating market growth.
Market Dynamics
Rising Global Immunization Programs Driving Market Growth
The expansion of immunization programs globally is a primary driver of the Pediatric Vaccine market. Governments and international organizations are investing heavily in vaccination campaigns to reduce infectious disease burden. According to WHO, global DTP3 vaccination coverage is approximately 84%, reflecting strong adoption of routine immunization. Furthermore, WHO data indicates that vaccination programs significantly reduce mortality rates among children under five years of age. Countries in Asia-Pacific and Africa are strengthening vaccine distribution networks and cold chain infrastructure to improve accessibility. Pharmaceutical companies are collaborating with governments to increase production capacity and expand vaccine availability. Between 2025 and 2026, companies are focusing on developing next-generation vaccines, including mRNA and combination vaccines, to enhance immunization efficiency. These initiatives are expected to drive sustained demand and improve vaccination rates globally.
High Development Costs and Distribution Challenges Limiting Market Growth
Despite strong demand, the Pediatric Vaccine market faces challenges related to high R&D costs and complex distribution requirements. Vaccine development involves extensive clinical trials, regulatory approvals, and manufacturing complexities, leading to high capital investment. According to OECD healthcare insights, maintaining cold chain logistics is essential for vaccine storage and transportation, increasing operational costs significantly. Supply chain disruptions and limited infrastructure in developing regions further complicate distribution. Additionally, regulatory hurdles and long approval timelines can delay product launches. To address these challenges, companies are investing in advanced manufacturing technologies and regional production facilities. Public-private partnerships and government funding are also supporting infrastructure development and improving vaccine accessibility, mitigating growth constraints.
Market Segmentation
- Based on the vaccine type, the market is segmented into live attenuated vaccines, inactivated (killed) vaccines, subunit, recombinant, polysaccharide & conjugate vaccines, mrna vaccines, and viral vector-based vaccines.
- Based on the vaccine composition, the market is segmented into monovalent vaccines and multivalent / combination vaccines.
- Based on the technology platform, the market is segmented into traditional vaccine platforms and next-generation platforms.
- Based on the end-user, the market is segmented into hospitals, pediatric clinics, and community health centers / vaccination camps.
Subunit, Recombinant, Polysaccharide & Conjugate Vaccines Segment Leads the Market
The subunit, recombinant, polysaccharide, and conjugate vaccines segment holds a dominant position in the Pediatric Vaccine market due to its strong safety profile, targeted immune response, and proven effectiveness in preventing bacterial infections such as pneumococcal and meningococcal diseases. These vaccines are designed to include only specific antigens rather than the whole pathogen, which significantly reduces the risk of adverse reactions while maintaining high efficacy, making them highly suitable for pediatric use. Their widespread inclusion in national immunization programs across developed and developing countries has further strengthened their market position. Governments and global health organizations prioritize these vaccines as part of routine childhood vaccination schedules, ensuring consistent demand and large-scale adoption. Additionally, increasing awareness about preventive healthcare and rising vaccination coverage in emerging economies are contributing to the segment’s continued growth. Leading pharmaceutical companies such as Pfizer Inc. and GSK plc. have actively expanded their portfolios in this segment between 2022 and 2026 through product innovation, enhanced formulations, and capacity expansion initiatives. These companies are also focusing on improving vaccine accessibility and distribution networks globally. The combination of strong clinical performance, regulatory support, and strategic industry investments continues to reinforce the dominance of this segment in the pediatric vaccine market.
mRNA Vaccines Segment to Record Strong Growth
The mRNA vaccines segment is projected to experience the fastest growth in the Pediatric Vaccine market, driven by significant advancements in biotechnology and the proven success of mRNA-based platforms in recent years. Unlike traditional vaccine approaches, mRNA vaccines use genetic instructions to stimulate the immune system, enabling rapid development, high precision targeting, and strong immune responses. These advantages have accelerated their adoption for pediatric applications, particularly in preventing infectious diseases. The flexibility and scalability of mRNA technology allow manufacturers to quickly adapt vaccines to emerging pathogens, making it a highly attractive solution in modern immunization strategies. As a result, pharmaceutical companies are increasingly investing in expanding their mRNA vaccine pipelines, focusing on developing new formulations specifically designed for children. These investments are also aimed at improving vaccine stability, delivery systems, and long-term efficacy.
Regional Outlook
The global pediatric vaccine market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).
United States Leads the Market
The United States dominates the Pediatric Vaccine market due to advanced healthcare infrastructure and high immunization coverage. According to the U.S. Food and Drug Administration (FDA), stringent regulatory frameworks ensure vaccine safety and efficacy, supporting market growth. Additionally, government programs such as Vaccines for Children (VFC) improve vaccine accessibility, driving consistent demand across the country. Strong presence of leading pharmaceutical companies further enhances innovation and market expansion.
India to Record Strong Growth
India is expected to witness strong growth due to expanding immunization programs and increasing healthcare investments. According to WHO, India has significantly improved vaccination coverage through national initiatives such as Mission Indradhanush. The country’s growing pharmaceutical manufacturing capabilities and increasing exports further support market expansion. Government efforts to improve rural healthcare infrastructure and vaccine accessibility are key factors driving growth in the region.
Competitive Landscape
The pediatric vaccine market is highly competitive and characterized by the presence of a few dominant global players that maintain strong market positions through extensive product portfolios, global distribution networks, and continuous innovation. Leading companies such as GSK plc., Merck & Co., Inc., Pfizer Inc., Sanofi, and Serum Institute of India Pvt. Ltd. collectively account for a significant share of the global market. These players leverage their strong research capabilities, established manufacturing infrastructure, and regulatory expertise to maintain a competitive edge. Competition in the market is primarily driven by technological innovation, product differentiation, and strategic collaborations. Companies are increasingly investing in next-generation vaccine platforms such as mRNA and recombinant technologies to enhance vaccine efficacy, reduce development timelines, and improve patient outcomes. Additionally, the development of multivalent and combination vaccines is becoming a key focus area, enabling companies to address multiple diseases with fewer doses, thereby improving compliance and expanding market reach.
Recent Developments
- In March 2026, Sanofi and Regeneron Pharmaceuticals received approval from Japan’s Ministry of Health, Labor and Welfare for Dupixent (dupilumab) to treat adults with moderate-to-severe bullous pemphigoid, based on LIBERTY-BP-ADEPT Phase 2/3 study results demonstrating significantly higher sustained disease remission compared to placebo, strengthening the product’s global dermatology portfolio.
- In March 2026, Merck & Co., Inc. announced the acquisition of Terns Pharmaceuticals, Inc. for approximately $6.7 billion to strengthen its oncology pipeline, particularly in hematology with TERN-701 for chronic myeloid leukemia, enhancing its portfolio diversification and long-term growth strategy.
- In March 2026, Serum Institute of India Pvt. Ltd. entered into a strategic collaboration with Eveliqure Biotechnologies GmbH to develop and commercialize novel anti-diarrhoeal vaccines targeting Shigella and ETEC, aiming to expand pediatric vaccine portfolios and accelerate global access through large-scale manufacturing and clinical development.
- In March 2026, GSK plc. received U.S. FDA approval to expand the age indication of Arexvy (RSV vaccine) to adults aged 18–49 years at increased risk of RSV-related lower respiratory tract disease, supported by Phase III trial data demonstrating strong immune response and safety, strengthening its RSV vaccine portfolio and expanding market reach.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualised market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global pediatric vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Pediatric Vaccine Market Sales Analysis – Vaccine Type | Vaccine Composition | Technology Platform | End-User ($ Million)
- Pediatric Vaccine Market Sales Performance of Top Countries
1.1 Research Methodology
- Primary Research Approach
- Secondary Research Approach
1.2 Market Snapshot
- Market Overview and Insights
2.1 Scope of the Study
2.2 Analyst Insight & Current Market Trends
2.2.1 Key Pediatric Vaccine Market Trends
2.2.2 Market Recommendations
2.3 Porter's Five Forces Analysis for the Pediatric Vaccine Market
2.3.1 Competitive Rivalry
2.3.2 Threat of New Entrants
2.3.3 Bargaining Power of Suppliers
2.3.4 Bargaining Power of Buyers
2.3.5 Threat of Substitutes
- Market Determinants
3.1 Market Drivers
3.1.1 Drivers For Global Pediatric Vaccine Market: Impact Analysis
3.2 Market Pain Points and Challenges
3.2.1 Restraints For Global Pediatric Vaccine Market: Impact Analysis
3.3 Market Opportunities
3.3.1 Opportunities For Global Pediatric Vaccine Market: Impact Analysis
- Competitive Landscape
4.1 Competitive Dashboard – Pediatric Vaccine Market Revenue and Share by Manufacturers
- Pediatric Vaccine Product Comparison Analysis
- Top Market Player Ranking Matrix
4.2 Key Company Analysis
4.2.1 GSK plc.
4.2.1.1 Overview
4.2.1.2 Product Portfolio
4.2.1.3 Financial Analysis
4.2.1.4 SWOT Analysis
4.2.1.5 Business Strategy
4.2.2 Merck & Co., Inc.
4.2.2.1 Overview
4.2.2.2 Product Portfolio
4.2.2.3 Financial Analysis
4.2.2.4 SWOT Analysis
4.2.2.5 Business Strategy
4.2.3 Pfizer Inc.
4.2.3.1 Overview
4.2.3.2 Product Portfolio
4.2.3.3 Financial Analysis
4.2.3.4 SWOT Analysis
4.2.3.5 Business Strategy
4.2.4 Sanofi
4.2.4.1 Overview
4.2.4.2 Product Portfolio
4.2.4.3 Financial Analysis
4.2.4.4 SWOT Analysis
4.2.4.5 Business Strategy
4.2.5 Serum Institute of India Pvt. Ltd.
4.2.5.1 Overview
4.2.5.2 Product Portfolio
4.2.5.3 Financial Analysis
4.2.5.4 SWOT Analysis
4.2.5.5 Business Strategy
4.3 Top Winning Strategies by Market Players
4.3.1 Merger and Acquisition
4.3.2 Product Launch
4.3.3 Partnership And Collaboration
- Global Pediatric Vaccine Market Sales Analysis by Vaccine Type ($ Million)
5.1 Live Attenuated Vaccines
5.2 Inactivated (Killed) Vaccines
5.3 Subunit, Recombinant, Polysaccharide & Conjugate Vaccines
5.4 mRNA Vaccines
5.5 Viral Vector-Based Vaccines
- Global Pediatric Vaccine Market Sales Analysis by Vaccine Composition ($ Million)
6.1 Monovalent Vaccines
6.2 Multivalent / Combination Vaccines
- Global Pediatric Vaccine Market Sales Analysis by Technology Platform ($ Million)
7.1 Traditional Vaccine Platforms
7.2 Next-Generation Platforms
- Global Pediatric Vaccine Market Sales Analysis by End-User ($ Million)
8.1 Hospitals
8.2 Pediatric Clinics
8.3 Community Health Centres / Vaccination Camps
- Regional Analysis
9.1 North American Pediatric Vaccine Market Sales Analysis – Vaccine Type | Vaccine Composition | Technology Platform | End-User Country ($ Million)
9.1.1 United States
9.1.2 Canada
9.2 European Pediatric Vaccine Market Sales Analysis – Vaccine Type | Vaccine Composition | Technology Platform | End-User | Country ($ Million)
9.2.1 UK
9.2.2 Germany
9.2.3 Italy
9.2.4 Spain
9.2.5 France
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Asia-Pacific Pediatric Vaccine Market Sales Analysis – Vaccine Type | Vaccine Composition | Technology Platform | End-User | Country ($ Million)
9.3.1 China
9.3.2 Japan
9.3.3 South Korea
9.3.4 India
9.3.5 Australia & New Zealand
9.3.6 ASEAN Countries
9.3.7 Rest of Asia-Pacific
9.4 Rest of the World Pediatric Vaccine Market Sales Analysis – Vaccine Type | Vaccine Composition | Technology Platform | End-User | Country ($ Million)
9.4.1 Latin America
9.4.2 Middle East and Africa
- Company Profiles
10.1 Bavarian Nordic
10.1.1 Quick Facts
10.1.2 Company Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.2 Beijing Minhai Biotechnology Co., Ltd
10.2.1 Quick Facts
10.2.2 Company Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.3 Bharat Biotech International Ltd
10.3.1 Quick Facts
10.3.2 Company Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.4 Bio-Farma
10.4.1 Quick Facts
10.4.2 Company Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.5 Biological E. Limited
10.5.1 Quick Facts
10.5.2 Company Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.6 CanSino Biologics Inc.
10.6.1 Quick Facts
10.6.2 Company Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.7 China National Biotec Group Co., Ltd
10.7.1 Quick Facts
10.7.2 Company Overview
10.7.3 Product Portfolio
10.7.4 Business Strategies
10.8 CSL Limited
10.8.1 Quick Facts
10.8.2 Company Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.9 Emergent BioSolutions Inc.
10.9.1 Quick Facts
10.9.2 Company Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.10 GC Biopharma
10.10.1 Quick Facts
10.10.2 Company Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.11 HAFFKINE Bio-Pharmaceutical Corporation Ltd.
10.11.1 Quick Facts
10.11.2 Company Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.12 Indian Immunologicals Limited
10.12.1 Quick Facts
10.12.2 Company Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.13 KM Biologics Co., Ltd.
10.13.1 Quick Facts
10.13.2 Company Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.14 Novavax, Inc.
10.14.1 Quick Facts
10.14.2 Company Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.15 Panacea Biotec Ltd.
10.15.1 Quick Facts
10.15.2 Company Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.16 Sinovac Biotech Ltd.
10.16.1 Quick Facts
10.16.2 Company Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.17 SK Bioscience Co., Ltd.
10.17.1 Quick Facts
10.17.2 Company Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.18 Takeda Pharmaceutical Company Limited
10.18.1 Quick Facts
10.18.2 Company Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.19 Valneva SE
10.19.1 Quick Facts
10.19.2 Company Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.20 Zydus Lifesciences Ltd.
10.20.1 Quick Facts
10.20.2 Company Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
1. Global Pediatric Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
2. Global Live Attenuated Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Inactivated (Killed) Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Subunit, Recombinant, Polysaccharide & Conjugate Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global mRNA Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Viral Vector-Based Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
7. Global Pediatric Vaccine Market Research and Analysis by Vaccine Composition, 2025–2035 ($ Million)
8. Global Pediatric Vaccine for Monovalent Vaccines Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Pediatric Vaccine for Multivalent / Combination Vaccines Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Pediatric Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Million)
11. Global Pediatric Vaccine for Traditional Vaccine Platforms Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Pediatric Vaccine for Next-Generation Platforms Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Pediatric Vaccine Market Research and Analysis by End-User, 2025–2035 ($ Million)
14. Global Pediatric Vaccine for Hospitals Research and Analysis by Region, 2025–2035 ($ Million)
15. Global Pediatric Vaccine for Pediatric Clinics Research and Analysis by Region, 2025–2035 ($ Million)
16. Global Pediatric Vaccine for Community Health Centers / Vaccination Camps Research and Analysis by Region, 2025–2035 ($ Million)
17. Global Pediatric Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
18. North America Pediatric Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
19. North America Pediatric Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
20. North America Pediatric Vaccine Market Research and Analysis by Vaccine Composition, 2025–2035 ($ Million)
21. North America Pediatric Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Million)
22. North America Pediatric Vaccine Market Research and Analysis by End-User, 2025–2035 ($ Million)
23. Europe Pediatric Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
24. Europe Pediatric Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
25. Europe Pediatric Vaccine Market Research and Analysis by Vaccine Composition, 2025–2035 ($ Million)
26. Europe Pediatric Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Million)
27. Europe Pediatric Vaccine Market Research and Analysis by End-User, 2025–2035 ($ Million)
28. Asia-Pacific Pediatric Vaccine Market Research and Analysis by Country, 2025–2035 ($ Million)
29. Asia-Pacific Pediatric Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
30. Asia-Pacific Pediatric Vaccine Market Research and Analysis by Vaccine Composition, 2025–2035 ($ Million)
31. Asia-Pacific Pediatric Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Million)
32. Asia-Pacific Pediatric Vaccine Market Research and Analysis by End-User, 2025–2035 ($ Million)
33. Rest of the World Pediatric Vaccine Market Research and Analysis by Region, 2025–2035 ($ Million)
34. Rest of the World Pediatric Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Million)
35. Rest of the World Pediatric Vaccine Market Research and Analysis by Vaccine Composition, 2025–2035 ($ Million)
36. Rest of the World Pediatric Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Million)
37. Rest of the World Pediatric Vaccine Market Research and Analysis by End-User, 2025–2035 ($ Million)
1. Global Pediatric Vaccine Market Share by Segment, 2025 Vs 2035 (%)
2. Global Live Attenuated Vaccine Market Share by Region, 2025 Vs 2035 (%)
3. Global Inactivated (Killed) Vaccine Market Share by Region, 2025 Vs 2035 (%)
4. Global Subunit, Recombinant, Polysaccharide & Conjugate Vaccine Market Share by Region, 2025 Vs 2035 (%)
5. Global mRNA Vaccine Market Share by Region, 2025 Vs 2035 (%)
6. Global Viral Vector-Based Vaccine Market Share by Region, 2025 Vs 2035 (%)
7. Global Pediatric Vaccine for Monovalent Vaccines Market Share by Region, 2025 Vs 2035 (%)
8. Global Pediatric Vaccine for Multivalent / Combination Vaccines Market Share by Region, 2025 Vs 2035 (%)
9. Global Pediatric Vaccine for Traditional Vaccine Platforms Market Share by Region, 2025 Vs 2035 (%)
10. Global Pediatric Vaccine for Next-Generation Platforms Market Share by Region, 2025 Vs 2035 (%)
11. Global Pediatric Vaccine for Hospitals Market Share by Region, 2025 Vs 2035 (%)
12. Global Pediatric Vaccine for Pediatric Clinics Market Share by Region, 2025 Vs 2035 (%)
13. Global Pediatric Vaccine for Community Health Centers / Vaccination Camps Market Share by Region, 2025 Vs 2035 (%)
14. Global Pediatric Vaccine Market Share by Region, 2025 Vs 2035 (%)
15. United States Pediatric Vaccine Market Size, 2025–2035 ($ Million)
16. Canada Pediatric Vaccine Market Size, 2025–2035 ($ Million)
17. UK Pediatric Vaccine Market Size, 2025–2035 ($ Million)
18. France Pediatric Vaccine Market Size, 2025–2035 ($ Million)
19. Germany Pediatric Vaccine Market Size, 2025–2035 ($ Million)
20. Italy Pediatric Vaccine Market Size, 2025–2035 ($ Million)
21. Spain Pediatric Vaccine Market Size, 2025–2035 ($ Million)
22. Russia Pediatric Vaccine Market Size, 2025–2035 ($ Million)
23. India Pediatric Vaccine Market Size, 2025–2035 ($ Million)
24. China Pediatric Vaccine Market Size, 2025–2035 ($ Million)
25. Japan Pediatric Vaccine Market Size, 2025–2035 ($ Million)
26. South Korea Pediatric Vaccine Market Size, 2025–2035 ($ Million)
27. Australia & New Zealand Pediatric Vaccine Market Size, 2025–2035 ($ Million)
28. ASEAN Pediatric Vaccine Market Size, 2025–2035 ($ Million)
29. Rest of Asia-Pacific Pediatric Vaccine Market Size, 2025–2035 ($ Million)
30. Latin America Pediatric Vaccine Market Size, 2025–2035 ($ Million)
31. Middle East & Africa Pediatric Vaccine Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of users within the company
